KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Expenses (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Operating Expenses for 6 consecutive years, with $143.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 23.6% year-over-year to $143.9 million, compared with a TTM value of $722.8 million through Dec 2025, up 34.39%, and an annual FY2025 reading of $722.8 million, up 34.39% over the prior year.
  • Operating Expenses was $143.9 million for Q4 2025 at Recursion Pharmaceuticals, down from $177.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $206.1 million in Q1 2025 and bottomed at $33.0 million in Q1 2021.
  • Average Operating Expenses over 5 years is $106.7 million, with a median of $101.3 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 138.73% in 2021, then decreased 23.6% in 2025.
  • Year by year, Operating Expenses stood at $67.5 million in 2021, then rose by 10.62% to $74.7 million in 2022, then soared by 47.1% to $109.8 million in 2023, then soared by 71.47% to $188.3 million in 2024, then fell by 23.6% to $143.9 million in 2025.
  • Business Quant data shows Operating Expenses for RXRX at $143.9 million in Q4 2025, $177.4 million in Q3 2025, and $195.4 million in Q2 2025.